Validation of a new high-performance liquid chromatography assay for nizatidine

被引:11
作者
Yusuf, A [1 ]
Al Dgither, S [1 ]
Hammami, MM [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Clin Res Ctr, Riyadh 11211, Saudi Arabia
关键词
nizatidine; bioavailability; bioequivalence; pharmacokinetics; high-performance liquid chromatography;
D O I
10.1097/01.ftd.0000189902.08684.90
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
An expedient high-performance liquid chromatography (HPLC) assay for nizatidine measurement in human plasma was developed and validated. After deproteinization of 200 mu L of plasma by filtration, nizatidine and 4-amino-antipyrine (internal standard) were separated (capacity ratio 3.0 and 6.63, respectively) on Nova-Pak C-18 cartridge at room temperature (RT), and detected spectrophotometrically at 320 nm. The mobile phase, 0.02 mol/L disodium hydrogen phosphate, acetonitrile, methanol, and triethylamine (80:10:10:0.05 vol/ vol), was delivered at 1.5mL/min. Calibration curves were linear (r(2) > 0.999) in the range 0.02 to 5 mu g/mL, detection and quantification limits were 0.01 and 0.02 mu g/mL, respectively, intra-run and inter-run coefficients of variation were <= 3.5% and <= 4.2%, respectively, and recovery was > 90%. Nizatidine was stable for at least 4 hours at RT, 12 weeks at - 20 degrees C, and 3 freeze-thaw cycles in plasma; 16 hours at RT and 48 hours at - 20 degrees C in deproteinized plasma; and 6 hours at RT and 3 weeks at - 20 degrees C in water.
引用
收藏
页码:232 / 236
页数:5
相关论文
共 21 条
[1]   The bioequivalence of nizatidine (Axid®) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule [J].
Abdel-Rahman, SM ;
Johnson, FK ;
Gauthier-Dubois, G ;
Weston, IE ;
Kearns, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (02) :148-153
[2]   Single-dose pharmacokinetics of nizatidine (Axid®) in children [J].
Abdel-Rahman, SM ;
Johnson, FK ;
Manowitz, N ;
Holmes, GB ;
Kearns, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (10) :1089-1096
[3]   The voltammetric behavior of nizatidine and its determination in biological fluids [J].
Al-Majed, AA ;
Belal, F ;
Al-Obaid, AM ;
Dawoud, AH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 21 (02) :319-326
[4]   Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects [J].
Blum, RA ;
Braverman, AJ ;
Rice, P ;
Johnson, FK .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01) :74-83
[5]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR NIZATIDINE, A NEW H-2 BLOCKER, IN HUMAN PLASMA AND URINE USING DISPOSABLE SOLID-PHASE EXTRACTION COLUMNS [J].
CARLUCCI, G .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 525 (02) :490-494
[6]   Kinetic spectrophotometric determination of nizatidine and ranitidine in pharmaceutical preparations [J].
Hassan, EM ;
Belal, F .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 27 (1-2) :31-38
[7]   Simultaneous high-performance liquid chromatographic analysis for famotidine, ranitidine HCl, cimetidine, and nizatidine in commercial products [J].
Ho, C ;
Huang, HM ;
Hsu, SY ;
Shaw, CY ;
Chang, BL .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (03) :379-385
[8]  
HUTCHINSON TA, DRUGDEX SYSTEM
[9]  
KAPETANOVIC V, 1994, FARMACO, V49, P377
[10]  
KNADLER MP, 1986, DRUG METAB DISPOS, V14, P175